Improved assessment in dense breasts
Mammographic sensitivity may fall to ~61% in BI‑RADS D tissue. Molecular signal is density‑independent.
Information for Clinicians
Overview
LiquidMammo™ is a supplemental, non‑invasive microRNA‑based liquid biopsy designed to strengthen breast‑cancer screening performance — particularly in dense‑breast populations where mammographic sensitivity is reduced.
LiquidMammo is currently being developed as a CLIA Laboratory Developed Test (LDT). It is not yet FDA‑cleared or FDA‑approved.
Why consider a supplemental molecular test?
Non‑invasive & easy to add
A routine blood draw — no radiation, no compression, minimal patient burden.
Supports clinical decision‑making
Provides complementary biological information to guide follow‑up, escalation, or imaging selection.
Biological rationale
microRNAs regulate gene expression across oncogenic pathways, including proliferation, immune modulation, DNA repair, and metastatic signaling. Their stability in blood and early dysregulation make them suitable biomarkers for screening support.
How the test works
1 — Order through your practice
The test is clinician‑ordered, like routine lab assays. Phlebotomy in‑clinic or via partner labs.
2 — Laboratory microRNA analysis
Plasma is processed under controlled SOPs. A tumor‑associated microRNA signature is quantified and analyzed.
3 — Clinician‑ready report
You receive a structured report including classification, density‑contextual interpretation, and recommendations.
Ideal patient populations
- Women with dense breasts (BI‑RADS C or D).
- Patients with elevated risk or family history.
- Patients who defer mammography due to anxiety, pain, or discomfort.
- Women under 50, where dense tissue is more common.
- Patients needing more frequent monitoring between imaging intervals.
Interpreting results
Negative / Low‑risk
Suggests no microRNA signature consistent with known cancer‑associated patterns. Continue guideline‑directed screening.
Positive / Elevated signal
Indicates microRNA changes associated with tumor biology. Consider further imaging (diagnostic mammography, ultrasound, MRI).
Results should always be interpreted alongside clinical history, density, and imaging.
Safety, quality, and compliance
CLIA environment
Testing is performed in a certified CLIA laboratory under strict SOPs, QC steps, and proficiency testing.
Sample integrity
Stabilized plasma collection ensures reproducibility. Chain‑of‑custody safeguards traceability.
Privacy & security
All patient data are de‑identified for analysis and processed under HIPAA‑aligned workflows.
Clinician enrollment
We are onboarding a limited number of clinical partners for validation and early access. Practices serving dense‑breasted and under‑screened populations are encouraged to inquire.